Rapamycin Increased Blood Flow in APOE4 Carriers

A clinical trial found low-dose rapamycin boosted cerebral circulation in participants with a genetic risk factor.

Updated on Sept. 30, 2026 in Alzheimer’s

Isometric editorial illustration featuring a crystalline glass neural structure with internal flow pathways, representing research on cerebral blood flow. — Researchers at the University of Missouri found that daily low-dose rapamycin significantly increased cerebral blood flow in study participants who carry the APOE4 gene. AI Illustration. Upload story photo >

Live Poll

Would you take a preventative drug now to reduce your future risk of Alzheimer's disease?

Researchers at the University of Missouri found that a daily 1 mg dose of rapamycin improved cerebral blood flow in APOE4 gene carriers by more than 15 percent. The four-week study focused on adults aged 45 to 65 who showed no signs of memory impairment or dementia.

Why it matters

The study investigated whether the FDA-approved immunosuppressant could reverse early circulatory decline associated with the APOE4 gene, which is a known genetic risk factor for Alzheimer's disease. These findings suggest a potential pathway for early intervention before clinical symptoms appear.

The clinical trial included 23 participants, consisting of nine APOE4 carriers and 14 non-carriers. Researchers observed that female APOE4 carriers experienced the most pronounced vascular improvements over the four-week period.

The players

University of Missouri

This public research university hosted the clinical trial at its Roy Blunt NextGen Precision Health building.

The details

Investigators at the Roy Blunt NextGen Precision Health building used neuroimaging to track how the daily medication influenced blood flow in the brains of participants. While the treatment yielded positive results for APOE4 carriers, non-carriers did not demonstrate significant changes in their vascular function during the trial.

September 2026: The study results were published in a scientific journal.

The Big Picture

This story follows a pattern established by the APOE4 genetic risk factor research by testing new pharmaceutical interventions against a known neurological vulnerability.

This research provides a new avenue for investigation into preventative measures for individuals with a genetic predisposition to memory decline. However, patients should not attempt to use immunosuppressants for this purpose without physician oversight and formal clinical trial participation.

The takeaway

The study suggests that targeting circulatory health may offer a strategy for mitigating Alzheimer's risk in high-risk genetic carriers. These early-stage results highlight the importance of future trials that track cognitive performance over extended periods.

What happens next

Researchers plan to expand these preliminary findings into larger, longitudinal clinical trials to confirm the long-term efficacy and safety of the intervention.